BIOTECON Diagnostics successfully finishes MicroVal certification
BIOTECON Diagnostics is the first company that has successfully MicroVal validated a real-time PCR system. Both of BIOTECON Diagnostics’ foodproof® Enterobacteriaceae plus E. sakazakii Detection Kits have been certified by Lloyd’s Register Nederland B.V. (Rotterdam, Netherlands), as well as Reagent D and the foodproof® StarPrep One Kit.
“24 external laboratories participated in the studies, including Nestlé, Eurofins, FrieslandCampina and SGS Germany, says Alois Schneiderbauer, Chief Business Officer (CBO) of BIOTECON Diagnostics.
With the globally recognized MicroVal certificate BIOTECON Diagnostics has set the stage for the global distribution of these products, which have been developed primarily for the baby food segment.
“With the achievement of this milestone we accomplish the increasing quality demands in the baby food industry, documenting our aim to cooperate with food producers in order to make food safer,“ says Kornelia Berghof-Jäger, Chief Executive Officer (CEO) of BIOTECON Diagnostics.
Other news from the department research and development
These products might interest you

Systec H-Series by Systec
Safe, reproducible and validatable sterilization of liquids, solids and waste
Autoclaves with 65-1580 liters usable space, flexibly expandable for various applications

Whatman™ folded filter papers by Cytiva
Whatman folded filter papers
Convenient folded formats speed up your sample preparation

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

Lonza Delivers Solid 2024 Performance with CER Sales in Line with Prior Year and 29.0% CORE EBITDA Margin - "Looking ahead to 2025 and beyond, we are focusing on implementing our One Lonza strategy..."
Amgen Completes Acquisition of Abgenix - Acquisition Provides Amgen with Full Ownership of Panitumumab and Eliminates a Denosumab Royalty
Focus Diagnostics - First U.S. Laboratory to License Newly Discovered Coronavirus CoV-NL63 From Primagen
